O
Opmed
Automates resource planning and allocation process to be resilient and optimized
About Opmed
Opmed.ai offers an AI-powered optimization platform tailored for the healthcare sector, with a specific focus on enhancing the operational efficiency of hospitals and other healthcare facilities. The company's core product is a sophisticated engine that leverages artificial intelligence and network science to address complex scheduling and resource allocation challenges. Initially targeting operating rooms (OR), the system optimizes scheduling to maximize utilization, reduce patient wait times, and improve overall throughput.
The platform's capabilities extend beyond the OR to other critical areas such as inpatient care, cath labs, and rehabilitation centers. By analyzing vast amounts of data, the system provides real-time, data-driven insights that empower hospital administrators to make informed decisions. It can predict demand, balance patient loads across different units, and optimize staff schedules, including those for nurses, based on real-time operational data. This approach helps to alleviate bottlenecks, prevent staff burnout, and ensure that resources are allocated where they are most needed.
The business model appears to be B2B, selling its SaaS solution directly to healthcare providers, including large hospital systems like Geisinger. The company generates revenue by licensing its platform. By demonstrating a clear return on investment through cost savings, increased revenue from higher patient throughput, and improved patient outcomes, Opmed.ai positions itself as a critical tool for modern healthcare management.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Ramat Gan, Israel
- Employees
- 62
- Open positions
- 3
- Dealroom signal
- 86.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2024 | $15M | $60M | Secret Chord Ventures · Sir Ronald Cohen · Grove Ventures · Operator Partners | ↗ |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | Bar-Ilan University | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Opmed is 3.8K monthly website visits, down 19.1% over the last three months. Opmed's team grew 10.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Grove Ventures
NFX
Secret Chord Ventures
Sir Ronald Cohen
Operator Partners
Launch It Capital- DYDanielle Yanai
- GSGuy Schory
Simon Legziel
unbox ventures
Other known investors1 additional known investor
Bar-Ilan University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Opmed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Opmed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







